Examples of using Soliris in English and their translations into Slovak
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
Most Recent Soliris Dose.
Using Soliris with food and drink.
Other information about Soliris.
How has Soliris been studied?
Timing of Supplemental Soliris Dose.
Why has Soliris been approved?
Therefore, you should not breast-feed while using Soliris.
Using Soliris with other medicines.
Instructions for Use for Healthcare Professionals Handling Soliris.
Soliris is used to treat adults and children with.
What benefit has Soliris shown during the studies?
Soliris was compared with placebo(a dummy treatment).
The Committee recommended that Soliris be given marketing authorisation.
Soliris was administered as an intravenous infusion over 25- 45 minutes.
The active substance in Soliris, eculizumab, is a monoclonal antibody.
Renal function, as measured by eGFR, was improved during Soliris therapy.
Supplemental Soliris Dose With Each Plasma Intervention.
Instructions for Use for Healthcare Professionals Handling Soliris.
The side effects caused by Soliris are usually mild or moderate.
Soliris should only be administered via intravenous infusion as described below.
Being carefully monitored by your doctor following any discontinuation of Soliris treatment.
Therefore, Soliris should be given to a pregnant woman only if clearly needed.
Soliris was more effective than placebo in improving the symptoms of PNH.
Inspect visually Soliris solution for particulate matter and discolouration.
Soliris is not expected to affect the aplastic component of anaemia in patients with PNH.
Each vial of Soliris contains 300 mg of active ingredient in 30 ml of product solution.
Dilute Soliris to a final concentration of 5 mg/ml(initial concentration divided by 2) by adding the appropriate amount of diluent to the infusion bag.
Administration of Soliris results in a rapid and sustained reduction in terminal complement activity.
Antibodies to Soliris were detected in 2% of patients with PNH using an ELISA assay and 3% of patients with aHUS using the ECL bridging format assay.